Advanced melanoma market seen reaching $6.37 billion by 2030

The Business Research Company projects the global advanced melanoma market will grow from $4.5 billion in 2026 to $6.37 billion by 2030. The report points to rising melanoma cases, stronger treatment adoption and faster growth in Asia-Pacific, with North America still the largest market in 2025.

Why it matters: - Advanced melanoma is a late-stage cancer that is harder to treat and often requires combination care. - The market outlook signals more demand for immunotherapy, targeted drugs and oncology infrastructure. - The report also points to rising sunburn rates as a public health factor linked to melanoma risk.

What happened: - The Business Research Company released its Melanoma Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the advanced melanoma market rose from $4.12 billion in 2025 to a projected $4.5 billion in 2026. - The report forecasts the market will reach $6.37 billion by 2030. - The report was published in London on Oct. 30, 2026. - A free sample of the report is available here. - The full report is available here.

The details: - The report says the 2025 to 2026 growth rate is 9.3%. - The report projects a 9.1% CAGR from 2026 to 2030. - Growth drivers cited for the recent period include limited treatment options for advanced disease, rising melanoma cases, improved hospital and oncology center infrastructure, greater awareness of skin cancer and wider use of chemotherapy and biological therapies. - Growth drivers for the forecast period include advances in immune checkpoint inhibitors, broader use of BRAF and MEK inhibitors, expanded personalized medicine, more investment in melanoma research and digital health tools for patient monitoring. - The report highlights widespread adoption of immunotherapy and targeted therapies as a key trend. - The report also cites biomarker-guided treatment selection, oncology center expansion, earlier detection, diagnostic innovation and more clinical trials. - Advanced melanoma includes stage III disease, which has spread to nearby lymph nodes, and stage IV disease, which has metastasized to distant organs. - Treatment often relies on immunotherapy, targeted therapy, chemotherapy or radiation.

Between the lines: - The market growth reflects both clinical need and a larger treatment ecosystem built around specialized cancer care. - Rising severe sunburn incidence adds a prevention and awareness dimension to what is often treated as a drug-market story. - North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report also includes South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa in its regional coverage. - New report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables.

What's next: - The report expects continued expansion as immunotherapy, targeted treatment and biomarker-driven care become more common. - The report also expects more clinical trials focused on advanced melanoma. - The Business Research Company is positioning the 2026 edition as a more data-heavy planning tool for market tracking and forecasting. - Melanoma Focus reported in May 2024 that UK hospital admissions for sunburn totaled 201 between 2022 and 2023, including 89 children and 25 infants under one year old. - Melanoma Focus also reported that 66% of UK adults aged 16-65 recalled getting sunburned as children, 65% had experienced blistering sunburn at least once and the share rose to 77% among people with light or pale skin.

The bottom line: - Advanced melanoma remains a small but fast-growing cancer market, with treatment innovation and disease burden pushing demand higher.